Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | Advances in GvHD management and prophylaxis

Alexandros Spyridonidis • 29 Oct 2022
COSTEM 2022
General Ruxolitinib

Alexandros Spyridonidis, MD, University of Patras, Patras, Greece, provides an overview of the latest developments in the prevention of graft-versus-host disease (GvHD). The approval of numerous treatments including ruxolitinib as well as cellular therapies being assessed in clinical trials will seek to improve outcomes in patients with chronic GvHD. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexandros Spyridonidis

The current role of MRD in allogeneic transplant for AML and unanswered questions that remain
2:08
The current role of MRD in allogeneic transplant for AML and unanswered questions that remain
Alexandros Spyridonidis • 24 Mar 2026
Cardiac comorbidities and PTCy-induced toxicity
1:07
Cardiac comorbidities and PTCy-induced toxicity
Alexandros Spyridonidis • 30 Mar 2025
Developing a new prognostic scoring system for post-alloSCT survival of patients with acute leukemia
2:01
Developing a new prognostic scoring system for post-alloSCT survival of patients with acute leukemia
Alexandros Spyridonidis • 30 Mar 2025
Can adding ATG to PTCy further reduce the risk of GvHD?
1:09
Can adding ATG to PTCy further reduce the risk of GvHD?
Alexandros Spyridonidis • 29 Oct 2022

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals